The Pen Needles Market is forecasted to reach $12.88 billion by 2031, growing at a compound annual growth rate (CAGR) of 9.9%, according to a recent report by Meticulous Research®. This growth is propelled by the increasing prevalence of diabetes, the rising demand for self-administration of medication, technological advancements in pen needles, and higher healthcare spending. Additionally, the shift in preference from traditional vials and syringes to pen needles, along with favorable reimbursement policies and expanding markets in emerging economies, is expected to present significant growth opportunities.
Market Challenges
Despite these positive trends, the market faces challenges such as concerns about needlestick injuries, the reuse of pen needles, limited access to healthcare in some developing regions, and a lack of awareness about proper pen needle usage.
Download Sample Copy: https://www.meticulousresearch.com/download-sample-report/cp_id=5796
Leading Companies
Prominent players in the pen needles market include: Becton, Dickinson and Company (U.S.), Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland), Owen Mumford Limited (U.K.), B. Braun Melsungen AG (Germany), Terumo Group (Japan), Allison Medical, Inc. (U.S.), Cardinal Health, Inc. (U.S.), UltiMed, Inc. (U.S.), Hindustan Syringes & Medical Devices Ltd (India), and Nanchang YiLi Medical Instrument Co.,LTD (China).
Future Market Segmentation
The pen needles market is segmented by:
Type: Standard Pen Needles, Safety Pen Needles
Needle Length: 4 mm, 5 mm, 6 mm, 8 mm, 10 mm, 12 mm & above
Usability: Single-use/Disposable, Reusable
Application: Insulin Therapy, Growth Hormone Therapy, GLP-1 Therapy, Other Applications
Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Healthcare Setting: Home Care, Hospitals & Clinics, Other Healthcare Settings
Key Segments
Type: Safety pen needles are projected to dominate the market in 2024, driven by their ability to reduce needlestick injuries, ensure safe and effective medication delivery, and provide better control during injection.
Needle Length: The 4 mm segment is expected to hold the largest market share in 2024, thanks to its ability to minimize pain during injections. Companies are also innovating in this space, such as Terumo Group's 2022 launch of the FineGlide sterile pen needle.
Usability: Single-use/disposable pen needles are set to lead in 2024 due to advancements in insulin delivery devices and heightened awareness of hygiene and needlestick safety.
Application: Insulin therapy is anticipated to dominate the application segment by 2024, fueled by the increasing global diabetes population and growing demand for insulin therapy. According to the International Diabetes Federation, the number of people with diabetes worldwide is projected to rise from 537 million in 2021 to 783 million by 2045.
Distribution Channel: Retail pharmacies are expected to be the largest distribution channel in 2024, offering greater convenience for patients who can access pen needles without a prescription.
Healthcare Setting: Home care is forecasted to be the leading segment in 2024, driven by increased awareness and adoption of diabetes management practices that empower patients to manage their care at home.
Get Customized Report: https://www.meticulousresearch.com/request-customization/cp_id=5796
Regional Insights
The report provides an in-depth analysis of key regions, including North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is expected to remain the largest market in 2023, largely due to its advanced healthcare infrastructure and the presence of leading industry players.
Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
